Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Common mechanisms in neurodegeneration

To the Editor:

Why, with all the progress in the field of neurodegeneration, do we still lack disease-modifying drugs that tackle the primary defect of severe cell loss? Part of the issue is that many cells are already dead before the symptoms appear, and we are probably attempting to treat the patients too late to make a difference. We still do not know whether the neurodegenerative disorders follow a unifying mechanism for disease initiation and propagation1. Accordingly, it is too soon to decide whether all these disorders should be treated in a similar fashion.

Neurodegeneration often results from the accumulation of misfolded aggregated proteins in different areas of the aging brain, and this process yields cell death and inflammatory damage in those brain areas. However, in some disorders, such as Huntington's disease, protein aggregates could have the opposite function, carrying out a protective role2. A recent study has challenged some of our ideas about Alzheimer's disease, concluding that tau aggregates seem to be a consequence rather than a cause of neurodegeneration3. Thus, it is unclear whether blocking this aggregation therapeutically would be beneficial or harmful.

The existence of common mechanisms for the pathogenesis of various neurodegenerative diseases could facilitate the development of new drugs to prevent these disorders. A probable common link among some of these disorders is the appearance of oxidative damage that results in neurodegeneration4. However, there is not enough work being done in the pharmaceutical industry to look for compounds that prevent oxidative stress or mitochondrial dysfunction.

More research should be done to determine whether there are common mechanisms for the different neurodegenerative disorders. This will aid in our understanding of disease mechanisms and will move drug development forward.

References

  1. Haass, C. Nat. Med. 16, 1201–1204 (2010).

    CAS  Article  Google Scholar 

  2. Arrasate, M., Mitra, S., Schweitzer, E.S., Segal, M.R. & Finkbeiner, S. Nature 431, 805–810 (2004).

    CAS  Article  Google Scholar 

  3. de Calignon, A. et al. Nature 464, 1201–1204 (2010).

    CAS  Article  Google Scholar 

  4. Lin, M.T. & Beal, M.F. Nature 443, 787–795 (2006).

    CAS  Article  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Jesús Avila.

Ethics declarations

Competing interests

The author declares no competing financial interests.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Avila, J. Common mechanisms in neurodegeneration. Nat Med 16, 1372 (2010). https://doi.org/10.1038/nm1210-1372a

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nm1210-1372a

Further reading

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing